	US 12,324,795 B2
	Autophagy activating agent
Junichiro Suzuki, Akitakata (JP); Yukihiro Kodera, Akitakata (JP); and Satomi Miki, Akitakata (JP)
Assigned to WAKUNAGA PHARMACEUTICAL CO. , LTD., Osaka (JP)
Appl. No. 16/972,414
Filed by WAKUNAGA PHARMACEUTICAL CO., LTD., Osaka (JP)
PCT Filed Jun. 6, 2019, PCT No. PCT/JP2019/022637 § 371(c)(1), (2) Date Dec. 4, 2020, PCT Pub. No. WO2019/235597, PCT Pub. Date Dec. 12, 2019.
Claims priority of application No. 2018-109700 (JP), filed on Jun. 7, 2018.
Prior Publication US 2021/0228521 A1, Jul. 29, 2021
Int. Cl. A61K 31/198 (2006.01); A23L 33/175 (2016.01); A61K 9/00 (2006.01); A61K 36/8962 (2006.01)

CPC A61K 31/198 (2013.01) [A23L 33/175 (2016.08); A61K 9/0053 (2013.01); A61K 36/8962 (2013.01); A61K 2236/333 (2013.01); A61K 2236/53 (2013.01)]

16 Claims

1. A method for treating or ameliorating a neurodegenerative disease comprising administering isolated S-1-propenylcysteine or a salt thereof to a subject.